Bifogade filer
PDF
Kurs
+26,68%
Likviditet
1,42 MSEK
Kalender
| Tid* | ||
| 2025-11-27 | 15:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | 15:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | 15:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | 16:30 | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | Årsstämma |
| 2024-03-22 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2024-03-01 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-25 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2023-02-10 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-25 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2022-03-24 | - | Årsstämma |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-12-30 | - | Extra Bolagsstämma 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-18 | - | Årsstämma |
| 2021-03-08 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-02 | - | Extra Bolagsstämma 2020 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2020-04-24 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-12-18 | - | Extra Bolagsstämma 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-29 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2019-04-26 | - | Årsstämma |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-27 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-23 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2018-04-20 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-28 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-02 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2017-05-29 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-26 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-01 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-29 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Klaria has been notified by the German Federal Institute for Drug and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) that the review process has concluded, and that marketing authorization for the treatment of migraine with and without aura is granted.
The review process was led by the German Federal Institute for Drug and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and applies to markets in Germany, Italy, and Spain. Further authorizations within the EU will be through the Mutual Recognition Procedure (MRP) and Repeat Use Procedure (RUP) established between European states (including the UK) for recognition of an approved medication in any other member state.
Klaria is in licensing discussions led by Ernst and Young which would cover all major markets in the EU and most member states, including the UK, representing over 30 million patients.
investor.relations@klaria.com (scott.boyer@klaria.com)